Mushroom Compounds and Tau Protein: Alzheimer's Mechanisms

Mushrooms & Alzheimer's Disease

Dual-target AD pathology

Tsai-Teng et al.'s 2016 study found erinacine A-enriched lion's mane mycelium reduced amyloid-β plaques, tau hyperphosphorylation, and neuroinflammation simultaneously in Alzheimer's transgenic mice, making it the only mushroom compound shown to address both of the disease's main pathological hallmarks in a single preclinical study.

Tsai-Teng et al., Journal of Biomedical Science, 2016

NGF

the neurotrophic protein lion's mane erinacines stimulate to support neuron health and growth

BBB

blood-brain barrier that erinacines cross to reach brain tissue, unlike hericenones from the fruiting body

2024

year of the first clinical trial testing ergothioneine for mild cognitive impairment

Tsai-Teng et al., Journal of Biomedical Science, 2016

View as image ↗

Most coverage of mushrooms and Alzheimer's disease focuses on amyloid plaques. This misses half the disease. Alzheimer's involves two distinct pathological processes running in parallel, and most drugs developed to target one have failed to stop the other. Li and colleagues' 2023 systematic review in Oxidative Medicine and Cellular Longevity mapped seven distinct AD pathological targets that mushroom compounds have been shown to engage: amyloid aggregation, tau hyperphosphorylation, cholinesterase inhibition, oxidative stress, neuroinflammation, ER stress, and mitochondrial dysfunction.^[1]

This article focuses on what makes mushroom compounds and tau protein research particularly interesting, and particularly honest about its limitations. It covers the specific compounds that affect tau pathology, the study that showed the most honest result (lion's mane reduced anxiety but not memory in a tau mouse model), the reishi mechanism that works through a completely different route, and the ergothioneine hypothesis that may explain population-level brain protection from eating mushrooms.

For the broader population data and human clinical evidence, see dietary mushroom intake and Alzheimer's risk: population studies and the brain health pillar.

Key Takeaways

Alzheimer's involves two distinct pathologies: amyloid-β plaques between neurons and tau tangles inside neurons; most failed AD drugs targeted only one; mushroom erinacines show preclinical evidence against both
Lai et al. (2013) showed lion's mane extracts promote neurite outgrowth via nerve growth factor (NGF) and BDNF pathways in neuronal cell culture, establishing the mechanistic foundation for erinacines' brain effects
Tsai-Teng et al. (2016) found erinacine A-enriched lion's mane mycelium reduced amyloid-β plaques, tau hyperphosphorylation, and neuroinflammation in Alzheimer's transgenic mice, while also improving spatial memory
Rodriguez et al. (2022) tested lion's mane in a tau-specific mouse model (rTg4510) for 4.5 months and found significant anxiolytic effects but NO improvement in spatial memory, a critical honest finding that challenges the memory narrative
Qi et al. (2021) showed reishi's ganoderic acid A works through a completely different mechanism: promoting amyloid-β clearance via autophagy activated by the Axl receptor, distinct from lion's mane's NGF pathway
Cheah et al. (2016) found elderly adults with mild cognitive impairment had significantly lower blood ergothioneine levels than cognitively normal controls; Ames et al. (2024) proposed ergothioneine deficiency as a causal factor in age-related neurodegeneration

The Two Ways Alzheimer's Destroys the Brain

Alzheimer's disease is not a single pathological process. It is characterized by two distinct types of protein accumulation that damage neurons through different mechanisms.

The first is amyloid-β plaques. Amyloid-β is a small protein fragment that is produced normally in the brain as a byproduct of neural activity. In Alzheimer's disease, amyloid-β accumulates between neurons and forms insoluble clumps called plaques. These plaques disrupt communication between neurons, trigger inflammation, and appear to be an early event in the disease.

The second is tau tangles. Tau is normally a structural protein inside neurons that helps stabilize the neuron's internal skeleton, allowing it to transport nutrients and signals along its length. In Alzheimer's disease, tau undergoes a chemical modification called hyperphosphorylation: extra phosphate groups are attached to the protein in ways that cause it to detach from the skeleton, collapse into clumps called neurofibrillary tangles, and block normal neuron function. Tau tangles appear later in the disease than amyloid plaques and are more closely correlated with cognitive symptoms.

The distinction matters for evaluating mushroom compound research. A compound that reduces amyloid plaques may not affect tau tangles, and vice versa. Most failed clinical trials for Alzheimer's drugs have targeted amyloid alone. A compound that addresses both pathological processes is mechanistically more comprehensive.

Abitbol and colleagues' 2022 review in Cells catalogued mushroom compounds as drug discovery leads for neurodegenerative diseases, identifying erinacines, ganoderic acids, ergothioneine, beta-glucans, and polysaccharides as the primary candidates, each with distinct mechanisms targeting different aspects of AD pathology.^[8]

The Neurotrophin Foundation: How Lion's Mane Talks to Neurons

Before covering the tau-specific evidence, it helps to understand what lion's mane compounds do in neural tissue. This is the biological basis on which the AD-specific research rests.

Lai and colleagues' 2013 study in the International Journal of Medicinal Mushrooms demonstrated that lion's mane (Hericium erinaceus) extracts promote neurite outgrowth in neuronal cell cultures.^[2] Neurites are the extensions that neurons grow to connect with neighboring cells; more and longer neurites mean more neural connectivity. The mechanism ran through two proteins: NGF (nerve growth factor, a protein that signals neurons to grow and branch) and BDNF (brain-derived neurotrophic factor, a related protein that supports neuron survival and memory formation).

Both fruiting body and mycelium of lion's mane produce compounds relevant to this mechanism, but they are different compounds with different properties. The fruiting body contains hericenones; the mycelium contains erinacines. Li and colleagues' 2018 review in Behavioural Neurology noted a critical practical difference: erinacines are small molecules (diterpenoids) that can cross the blood-brain barrier, the protective filter around the brain that blocks most compounds from entering the bloodstream.^[3] Hericenones are larger and have not been shown to cross it in the same way. This is why most of the specific AD preclinical research uses erinacine-enriched mycelium preparations rather than fruiting body extracts.

Erinacine A: The Compound That Attacked Both Tau and Amyloid

The most comprehensive preclinical study of lion's mane against Alzheimer's pathology was conducted by Tsai-Teng and colleagues in 2016, using mice genetically engineered to develop both amyloid plaques and tau tangles, two of the hallmarks of human Alzheimer's disease.^[4]

The mice were supplemented with erinacine A-enriched lion's mane mycelium for 30 days. The results: amyloid-β plaque burden in the hippocampus was reduced; tau hyperphosphorylation in brain tissue was reduced; neuroinflammation markers (including activated astrocytes and microglia, the brain's immune cells) were reduced; and the treated mice showed better spatial memory performance on maze tests compared to untreated controls.

This is the most mechanistically comprehensive mushroom compound study in AD animal models to date. The finding that erinacine A attacks both the amyloid pathway and the tau pathway simultaneously, through the single mechanism of promoting NGF production, is what distinguishes it from most experimental AD interventions that target only one pathway.

The mechanism proposed by Tsai-Teng's team: erinacine A stimulates NGF production in neurons. NGF supports neuron health and maintains the internal cellular machinery that processes amyloid precursor protein correctly. Healthy neurons process this precursor in a way that does not produce the harmful amyloid-β fragments that form plaques; damaged or stressed neurons process it differently, generating more amyloid-β. Separately, adequate NGF supports the tau stabilization machinery that prevents hyperphosphorylation. Both pathological processes benefit from restoring NGF signaling.

The 2020 pilot human trial by Li and colleagues in Frontiers in Aging Neuroscience tested erinacine A-enriched lion's mane mycelium in 49 patients with mild Alzheimer's disease for 49 weeks.^[5] The result requires careful reading. Participants in the treatment group showed significantly improved Instrumental Activities of Daily Living scores compared to placebo. IADL measures complex practical tasks: managing finances, preparing meals, using a telephone, taking medications correctly. This is a meaningful clinical outcome.

However, the MMSE (Mini-Mental State Examination), the standard cognitive screening test measuring memory, orientation, and language, showed no significant difference between groups. Improved IADL without improved MMSE suggests the treatment may have supported functional capacity or slowed decline in practical skills while not meaningfully improving or preserving cognitive test performance. This nuance is entirely absent from most coverage of this study, which reports "improved outcomes in AD patients" without specifying what improved and what did not.

The Tau Mouse Result That No One Discusses

The most intellectually honest piece of evidence in the lion's mane and tau story is from Rodriguez and colleagues' 2022 study in Behavioural Sciences.^[6]

Rodriguez's team used a mouse model called rTg4510. These mice are engineered to overproduce a mutant form of tau, developing severe tau tangles similar to those seen in human Alzheimer's disease. This is a tau-specific model, distinct from the amyloid-plus-tau model used by Tsai-Teng. It allows researchers to isolate what lion's mane does specifically against tau pathology, without the confounding variable of simultaneous amyloid changes.

The mice were fed a lion's mane-supplemented diet for 4.5 months.

The finding: lion's mane produced significant anxiolytic effects. The treated mice spent more time in the open areas of a maze (a standard test for reduced anxiety), showing less of the anxiety-driven behavior that is elevated in the tau-overexpressing mice.

But spatial memory was not improved. The maze tasks measuring spatial learning and memory (the cognitive functions most directly relevant to Alzheimer's disease progression) showed no significant benefit compared to controls.

This is a different result from the Tsai-Teng study, and both results can be accurate. The difference is likely the mouse model: Tsai-Teng's mice have both amyloid and tau pathology; erinacine A's effects on NGF address both. Rodriguez's mice have only tau overexpression without the amyloid component. If erinacine A's cognitive benefits in Tsai-Teng's model operated primarily through reducing amyloid-driven damage, those benefits would not appear in a pure-tau model.

The honest interpretation: lion's mane erinacines show anxiolytic properties in tau pathology models, which may be clinically relevant for the anxiety and mood symptoms that often accompany AD, but the cognitive/memory effects observed in the amyloid-plus-tau model may depend on the presence of both pathologies to be detectable.

Reishi's Different Route: Amyloid Clearance Through Autophagy

Qi and colleagues' 2021 study in International Journal of Molecular Sciences described a mechanism for ganoderic acid A (GAA), a triterpenoid from reishi mushroom (Ganoderma lucidum), that is entirely distinct from lion's mane's NGF pathway.^[7]

The mechanism: GAA activates a receptor called Axl on the surface of neurons. When Axl is activated, it triggers a cellular process called autophagy, the cell's self-cleaning system that breaks down and recycles damaged or misfolded proteins. One of the proteins that autophagy can clear is amyloid-β. Neurons that have activated autophagy via Axl more efficiently break down amyloid-β before it can aggregate into plaques.

In cell culture, GAA promoted amyloid-β clearance via this autophagy pathway. In an AD mouse model, GAA administration improved cognitive performance on spatial memory tasks compared to untreated controls. No improvement was seen in control mice without AD pathology, confirming the effect was specific to the diseased state.

The GAA mechanism is complementary to lion's mane's NGF mechanism. Lion's mane erinacines primarily support neuron health and reduce tau pathology by maintaining NGF-dependent cellular machinery. Reishi ganoderic acids promote the active cleanup of amyloid-β through autophagy. These two mechanisms could theoretically work together in a way that neither compound alone can achieve.

Neither compound has been tested against tau pathology in the same study, and no human clinical trial of ganoderic acid A for AD has been published. Qi's 2021 study is animal-model and cell-culture evidence for the mechanism; translation to clinical efficacy remains undemonstrated.

Ergothioneine: The Population-Level Brain Protector

The epidemiological evidence for mushrooms and lower dementia risk (the Singapore MCI study, the US NHANES data, the Japanese CIRCS cohort) converges on a specific proposed mechanism: ergothioneine.

Ergothioneine is an antioxidant amino acid produced almost exclusively by fungi. Humans cannot synthesize it; we must obtain it from the diet. Mushrooms are by far the richest dietary source. The human body actively transports ergothioneine across cell membranes using a specific transporter protein, concentrating it in cells with high oxidative stress: red blood cells, liver cells, kidney cells, and crucially, mitochondria in neurons.

Cheah and colleagues' 2016 study in Biochemical and Biophysical Research Communications examined ergothioneine blood levels in elderly participants and found that those with mild cognitive impairment had significantly lower ergothioneine levels than cognitively normal controls, with lower levels correlating with greater cognitive decline.^[9] This is consistent with ergothioneine being depleted by the elevated oxidative stress and mitochondrial dysfunction that characterizes neurodegeneration.

Ames and colleagues' 2024 review proposed a more specific causal claim: that ergothioneine deficiency may be a contributing cause of age-related neurodegenerative diseases, not just a correlate.^[10] The hypothesis rests on several observations: older adults absorb ergothioneine less efficiently than younger adults (reducing dietary intake's effectiveness); populations that eat more mushrooms consistently show lower rates of neurodegenerative disease in epidemiological data; and ergothioneine's protective effects in neural tissue are mechanistically specific to the types of oxidative damage that accumulate in AD and Parkinson's disease.

Zou and colleagues' 2024 animal study extended this: ergothioneine supplementation extended lifespan in male mice and improved both cognitive and physical performance measures during aging compared to unsupplemented controls.^[11] This provides the preclinical confirmation that the correlation seen in Cheah's human data reflects a real biological effect rather than a confounding factor.

The direct human clinical test is the Tan et al. 2024 trial, which specifically investigated whether ergothioneine supplementation could slow cognitive decline in adults with mild cognitive impairment.^[12] This is the first controlled human study of ergothioneine as a direct cognitive intervention rather than a dietary observation. The trial's results are the most directly relevant human clinical data for the ergothioneine hypothesis.

The significance of the ergothioneine story extends beyond lion's mane or reishi specifically. Every common edible mushroom, including white button mushrooms, oyster mushrooms, and shiitake, contains ergothioneine. The population-level association between mushroom consumption and lower dementia risk may reflect the cumulative effect of regular ergothioneine intake from ordinary dietary mushrooms, regardless of whether those mushrooms are medicinal species. This is a mechanistic story about food-as-medicine that does not require exotic supplement species.

What the Evidence Picture Actually Tells Us

Taken together, the mushroom compound and tau/AD research presents a specific picture.

Erinacines from lion's mane mycelium have the strongest preclinical evidence for directly affecting both amyloid and tau pathology through NGF stimulation, with one human pilot study in mild AD showing functional improvement but no measured cognitive score improvement. The tau-specific mouse model result (anxiolytic without cognitive benefit) adds important nuance to what erinacines actually do in tau-dominant pathology.

Ganoderic acid A from reishi has a mechanistically distinct and complementary mechanism through autophagy, with animal model cognitive benefits and zero human AD trial data.

Ergothioneine, found in all edible mushrooms, may be the compound that explains population-level epidemiological associations between mushroom consumption and lower dementia rates. It is a mechanism about mitochondrial protection and oxidative stress that operates over years of habitual intake rather than in acute supplementation studies.

The honest evidence state: strong mechanistic rationale, compelling preclinical data, limited human clinical evidence, and no large-scale AD-specific randomized controlled trial for any mushroom compound. The 2025 narrative review by Ratto and colleagues concluded that lion's mane has meaningful preclinical support for AD but called explicitly for larger, adequately powered human trials before the question of clinical efficacy can be answered.

For the cross-species comparison of lion's mane, reishi, and Cordyceps with separate mechanism tables, see cross-species mushroom research in Alzheimer's. For the Singapore Diet and Aging Study that provides some of the strongest population evidence, see the Singapore mushroom study.

The Bottom Line

Alzheimer's disease involves two distinct pathological processes: amyloid-β plaques between neurons and tau hyperphosphorylation inside neurons. Erinacine A from lion's mane mycelium is the only mushroom compound shown to address both simultaneously in a preclinical model (Tsai-Teng 2016), operating through NGF stimulation that maintains healthy neuron metabolism. Li et al.'s 2020 pilot RCT found improved functional activities but no cognitive score improvement in mild AD patients. Rodriguez et al.'s 2022 tau-specific mouse model study found lion's mane produced anxiolytic effects without spatial memory improvement, an important honest boundary on what erinacines do against pure tau pathology. Qi et al. (2021) showed reishi's ganoderic acid A reduces amyloid-β through autophagy (Axl receptor activation), a distinct and potentially complementary mechanism. Ergothioneine, present in all edible mushrooms, shows an emerging clinical picture connecting depleted blood levels with cognitive decline and longevity extension in animal models, with a 2024 clinical trial directly testing its efficacy in mild cognitive impairment.

Frequently Asked Questions

Tau is normally a structural protein inside neurons that stabilizes the internal transport system. In Alzheimer's disease, tau undergoes hyperphosphorylation: excess phosphate groups are attached to the protein chemically, causing it to detach from the neuron's internal skeleton, misfold, and clump into neurofibrillary tangles. These tangles block normal neuron function and eventually cause the neuron to die. Tau tangles appear later than amyloid plaques but are more closely correlated with cognitive symptoms. Erinacine A from lion's mane mycelium reduced tau hyperphosphorylation in Alzheimer's transgenic mice in Tsai-Teng et al.'s 2016 study, likely by maintaining the NGF-dependent cellular machinery that regulates tau phosphorylation.

In animal models, erinacine A-enriched lion's mane mycelium reduced tau hyperphosphorylation in Alzheimer's transgenic mice while also reducing amyloid plaques and neuroinflammation (Tsai-Teng 2016). However, a separate tau-specific mouse model study (Rodriguez 2022) found anxiolytic effects from lion's mane without improvement in spatial memory, suggesting the cognitive effects may depend on the presence of both tau and amyloid pathology. No human clinical trial has measured tau protein levels in response to any mushroom compound. Human evidence is limited to a 2020 pilot study in mild AD patients showing improved daily functioning but not cognitive scores.

Erinacines from lion's mane mycelium reduced tau hyperphosphorylation in a 2016 transgenic AD mouse model study, alongside reductions in amyloid plaques and neuroinflammation. Erinacines work by stimulating nerve growth factor, which helps neurons maintain the cellular machinery that processes proteins correctly. However, Rodriguez et al.'s 2022 study specifically using a tau-overexpressing mouse model (without amyloid pathology) found lion's mane produced anxiolytic effects but no improvement in spatial memory. This suggests that the cognitive benefits seen when both pathologies are present may depend partly on the amyloid-reduction component rather than tau reduction alone.

Amyloid-β plaques form outside neurons, accumulating between brain cells and disrupting their communication; they are thought to be an early event in Alzheimer's development. Tau tangles form inside neurons, where misfolded tau protein clumps within the neuron's internal structure and eventually kills the cell; tau tangles appear later than amyloid plaques and correlate more closely with cognitive decline. Both pathologies are required for an Alzheimer's diagnosis. Most clinical trials have targeted amyloid alone, and most have failed. Erinacine A from lion's mane is unusual in that the 2016 Tsai-Teng mouse study showed preclinical effects on both pathologies simultaneously.

Neuroinflammation is a third component of Alzheimer's pathology alongside amyloid and tau, and multiple mushroom compounds show anti-neuroinflammatory effects. Erinacine A from lion's mane reduced activated astrocytes and microglia (the brain's immune cells when overactive) in Alzheimer's transgenic mice. Ganoderic acid A from reishi promotes autophagy-mediated clearance of amyloid, reducing one trigger for neuroinflammation. Ergothioneine, found in all common edible mushrooms, specifically concentrates in brain mitochondria and protects against oxidative stress-driven inflammation. Abitbol et al.'s 2022 review identified erinacines, ganoderic acids, ergothioneine, and beta-glucans as the primary mushroom compound classes with documented anti-neuroinflammatory mechanisms in the context of neurodegeneration.

Sources & References

1. Source details for this reference are not yet available.
2. Source details for this reference are not yet available.
3. Source details for this reference are not yet available.
4. Source details for this reference are not yet available.
5. Source details for this reference are not yet available.
6. Source details for this reference are not yet available.
7. Source details for this reference are not yet available.
8. Source details for this reference are not yet available.
9. Source details for this reference are not yet available.
10. Source details for this reference are not yet available.
11. Source details for this reference are not yet available.
12. Source details for this reference are not yet available.